CAJ | 학술논문

目的：评价替罗非班在急诊经皮冠状动脉介入治疗（ PCI ）的疗效及安全性。方法急诊收治的行PCI术患者87例，随机分为试验组41例和对照组46例，在常规抗凝治疗基础上，试验组于 PCI 术前早期静脉推注替罗非班10 mg· kg-1，然后以0.15μg· kg-1· min-1持续泵入至术后36 h；对照组只于PCI术前常规抗凝治疗。观察2组患者术后主要不良心血管事件（ MACE）、心肌酶指标及出血并发症。结果试验组MACE发生率为9.8％（4/41），显著低于对照组26.1％（12/46），差别有统计学意义（ P＜0.05）；试验组术后24 h心肌酶显著低于对照组（P ＜0.05）；2组患者出血并发症差别无统计学意义（P ＞0.05）。结论急诊PCI患者早期用替罗非班可显著降低MACE发生率，且不增加术后出血发生的风险。
목적：평개체라비반재급진경피관상동맥개입치료（ PCI ）적료효급안전성。방법급진수치적행PCI술환자87례，수궤분위시험조41례화대조조46례，재상규항응치료기출상，시험조우 PCI 술전조기정맥추주체라비반10 mg· kg-1，연후이0.15μg· kg-1· min-1지속빙입지술후36 h；대조조지우PCI술전상규항응치료。관찰2조환자술후주요불양심혈관사건（ MACE）、심기매지표급출혈병발증。결과시험조MACE발생솔위9.8％（4/41），현저저우대조조26.1％（12/46），차별유통계학의의（ P＜0.05）；시험조술후24 h심기매현저저우대조조（P ＜0.05）；2조환자출혈병발증차별무통계학의의（P ＞0.05）。결론급진PCI환자조기용체라비반가현저강저MACE발생솔，차불증가술후출혈발생적풍험。
Objective To evaluate the clinical efficacy and safety of tirofiban in the treatment of patients who received percutaneous coronary intervention( PCI).Methods Eighty-seven patients with acute coro-nary syndrome treated with PCI were recruited from Feb 2011 to Sep 2013 prospectively.They were randomly divided into treatment group ( n=41 ) and control group ( n=46 ).Based on the regular anticoagulant therapy , patients in the treatment group were given tirofiban 10 mg· kg-1 immediately at the early time of pre -PCI, followed by 0.15μg· kg -1 · min -1 intravenous infusion until 36 hours after PCI.Patients in the control group were only given the regular anticoagulant therapy at the early time of pre-PCI.And the major adverse cardiovascular events (MACE), myocardial enzymes and complication of the two groups were observed in the two groups.Results The rate of MACE (9.8%, 4/41) in treatment group were much lower than that in the control group (26.1%, 12/46) ( P<0.05 ).The myocardial enzyme indicators of 24 hours after PCI was lower than that in the control group;but there was no difference in bleeding complications between the two groups ( P>0.05 ) . Conclusion MACE can be significantly decreased in patients who were treated with PCI by using tirofiban in the emergency department and tiro-fiban does not increase the risks to develop bleeding complications.